UPPSALA, SE / ACCESS Newswire / April 22, 2026 / Senzime (STO:SEZI) (OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - March 2026 is now available on the company's website information ...
The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagementASPIRE is designed to assess the effect of ...
Patent grant reinforces long-term US protection of the MET platform underpinning Nanomerics' ocular and nose-to-brain drug delivery pipelines. LONDON, UK / ACCESS Newswire / April 22, 2026 / ...
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...
AV Laboratories is redefining the future of skincare by translating decades of advanced biotechnology research into ...
Ono Pharmaceuticals Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced two upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) ...
Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today provided an update that Garda Therapeutics, Inc. (“Garda”) intends to commence the tender offer to acquire all outstanding ...
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the acceptance of an abstract for poster presentation at the ...
Signing of a two-year shareholder loan agreement for up to €6.0 million, of which €1.5 million paid upon signing, repayable in new shares representing up to 7.6% of the Company’s share capital or in ...
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous ...
Acquisition builds on UCB’s 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies.Lead investigational asset, NRTX-1001, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results